Brentuximab Vedotin in CD30-Positive Lymphoma

Panelists: Myron S. Czuczman, MD, Roswell Park; Steve M. Horwitz, MD, MSKCC;
Lauren C. Pinter-Brown, MD, UCLA; Andrei R. Shustov, MD, SCCA; Anas Younes, MD, MSKCC
Published Online: Wednesday, March 12, 2014
For High-Definition, Click
In August 2011, the FDA granted an accelerated approval to brentuximab vedotin as a treatment for patients with systemic anaplastic large-cell lymphoma (ALCL) based on a single-arm clinical trial. This study enrolled 58 patients with CD30-positive systemic ALCL following front-line treatment with chemotherapy.

In the study, 86% of patients achieved an objective response (complete response = 57%; partial response = 29%). In addition to response rates, a plateau in progression-free survival and overall survival is evident for some patients, Andrei R. Shustov, MD, suggests.

As a result of these responses, some patients are able receive a consolidative transplantation. However, more impressively, Shustov believes, are the elderly patients who refused consolidative therapy and respond to treatment with brentuximab for longer than 2 years.

At this point, it remains unclear whether brentuximab could be used as a maintenance therapy. Additionally, Shustov notes, the optimal number of treatment cycles to administer is unknown for patients who experience a complete response. Despite these concerns, studies have suggested that patients who stop taking the drug and then relapse will continue to respond to brentuximab when treatment is re-administered, Shustov states.

Brentuximab is also being explored as a treatment for patients with cutaneous T-cell lymphoma (CTCL), notes Lauren C. Pinter-Brown, MD. A phase II study in patients with relapsed or refractory mycosis fungoides with variable CD30 expression showed an objective response rate of 70%. This led to the initiation of a phase III study examining brentuximab versus physician’s choice in patients with CD30-positive CTCL, Pinter-Brown notes.

In the CTCL studies, CD30 expression was measured by IHC from biopsies of skin lesions. At this point, there doesn’t appear to be a correlation between IHC staining and response, Pinter-Brown suggests.

In a broad phase II study looking at patients with greater than 1% CD30 expression, there appeared to be high response rate in patients with angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified, Steve M. Horwitz, MD, notes. These studies found that patients who responded to brentuximab had elevated serum levels of soluble CD30. This data suggests that IHC may not be the most effective test for the detection of clinically meaningful CD30 positivity, Horwitz believes.
View More From This Discussion
Episode 1 Introduction: Antibody-Drug Conjugates in Lymphoma
Episode 2 Brentuximab Vedotin in CD30-Positive Lymphoma
Episode 3 Brentuximab Vedotin-Induced Peripheral Neuropathy
Episode 4 Novel ADCs in Development for Lymphoid Malignancies
Episode 5 Role of Radiation Therapy in Hodgkin Lymphoma
Episode 6 Frontline Treatment of Hodgkin Lymphoma
Episode 7 Pretransplant Brentuximab Vedotin in Hodgkin Lymphoma
Episode 8 Novel Agents and Combinations in Hodgkin Lymphoma
Episode 9 Exploratory Therapies for Hodgkin Lymphoma
Episode 10 Treatment Selection for Peripheral T-cell Lymphoma
Episode 11 Novel Treatment Strategies for PTCL
Episode 12 Novel Agents and Chemotherapy Regimens in PTCL
Episode 13 Lymphoid Malignancy Treatment Considerations
Expert Panelists
Dr Myron S. Czuczman

Myron S. Czuczman, MD

Chief, Lymphoma/Myeloma Service, Department of Medicine
Head, Lymphoma Translational Research Laboratory, Department of Immunology,
Roswell Park Cancer Institute

Steve M. Horwitz, MD

Associate Attending Medical Oncologist,
Lymphoma Service, Memorial Sloan Kettering Cancer Center

Lauren C. Pinter-Brown, MD

Clinical Professor of Medicine
The Geffen School of Medicine,
University of California, Los Angeles

Andrei R. Shustov, MD

Assistant Professor, Hematology Division, University of Washington School of Medicine and the Seattle Cancer Care Alliance

Anas Younes, MD

Chief, Lymphoma Service,
Memorial Sloan-Kettering Cancer Center
Online CME Activities
Free CME from PER
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung Cancer
Medical Crossfire®: The JAK-STAT Pathway as a Mediator of Onco-Inflammation
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case Discussion
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
More Reading